Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Larimar Therapeutics Inc (LRMR)

17.15   -0.45 (-2.56%) 03-03 15:13
Open: 17.43 Pre. Close: 17.6
High: 17.51 Low: 17.1
Volume: 29,272 Market Cap: 247M
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound is CTI-1601, a Phase 1 clinical program to treat Friedreich's ataxia, a rare and progressive genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 17.683 - 17.754 17.754 - 17.822
Low: 16.627 - 16.704 16.704 - 16.778
Close: 17.473 - 17.597 17.597 - 17.716

Technical analysis

as of: 2021-03-03 2:54:25 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 21.58     One year: 24.00
Support: Support1: 15.11    Support2: 12.57
Resistance: Resistance1: 18.47    Resistance2: 20.55
Pivot: 18.17
Moving Average: MA(5): 17.26     MA(20): 18.42
MA(100): 19.75     MA(250): 40.48
MACD: MACD(12,26): -0.51     Signal(9): -0.42
Stochastic oscillator: %K(14,3): 28.05     %D(3): 25.80
RSI: RSI(14): 41.33
52-week: High: 185.76  Low: 9.01  Change(%): -89.9
Average Vol(K): 3-Month: 6357  10-Days: 6413

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
LRMR has closed above bottom band by 21.2%. Bollinger Bands are 26.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 01 Mar 2021
Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Yahoo Finance

Thu, 18 Feb 2021
Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference - GlobeNewswire

Tue, 16 Feb 2021
Feb 16, 2021 - Logos Global Management LP Buys Olema Pharmaceuticals inc, Nkarta Inc, Kinnate Biopharma Inc, Sells Global Blood Therapeutics Inc, Keros Therapeutics Inc, Sarepta Therapeutics Inc - GuruFocus.com

Mon, 08 Feb 2021
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth - Simply Wall St

Fri, 13 Nov 2020
Larimar Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Tue, 10 Nov 2020
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results - GlobeNewswire

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 15
Shares Float (M) 5
% Held by Insiders 2.88
% Held by Institutions 88.77
Shares Short (K) 202
Shares Short P. Month (K) 162

Stock Financials

EPS
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -2.242
Qtrly Earnings Growth
Operating Cash Flow (M) -40
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow -6.53

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.